KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EBIT (2016 - 2025)

Historic EBIT for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $217.9 million.

  • Halozyme Therapeutics' EBIT rose 3353.25% to $217.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $737.4 million, marking a year-over-year increase of 5458.79%. This contributed to the annual value of $551.5 million for FY2024, which is 6336.42% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' EBIT is $217.9 million, which was up 3353.25% from $202.4 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' EBIT peaked at $217.9 million during Q3 2025, and registered a low of $34.1 million during Q2 2022.
  • For the 5-year period, Halozyme Therapeutics' EBIT averaged around $105.0 million, with its median value being $93.0 million (2021).
  • Its EBIT has fluctuated over the past 5 years, first surged by 167415.45% in 2021, then tumbled by 6339.48% in 2022.
  • Halozyme Therapeutics' EBIT (Quarter) stood at $56.5 million in 2021, then skyrocketed by 31.8% to $74.5 million in 2022, then skyrocketed by 35.6% to $101.0 million in 2023, then soared by 73.7% to $175.5 million in 2024, then increased by 24.17% to $217.9 million in 2025.
  • Its EBIT was $217.9 million in Q3 2025, compared to $202.4 million in Q2 2025 and $141.5 million in Q1 2025.